Literature DB >> 2112460

A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen. cDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue.

M Hareuveni1, I Tsarfaty, J Zaretsky, P Kotkes, J Horev, S Zrihan, M Weiss, S Green, R Lathe, I Keydar.   

Abstract

A monoclonal antibody, H23, that specifically recognizes a breast-tumor-associated antigen, was used to isolate a cDNA insert that codes for the antigenic epitope. Nucleotide sequencing of this cDNA, as well as a longer 850-bp cDNA insert, shows that they are composed of 60-bp (G + C)-rich tandem repeating units. The coding strand was determined and codes for a proline-rich 20-amino-acid repeat motif. A comparison of the highly conserved repeat unit with the deduced flanking amino acid sequences demonstrates conservation of specific subregions of the repeat consensus within the flanking amino acids. Hybridization of the 60-bp cDNA probe with RNAs extracted from a variety of primary and metastatic human tumors yields relatively high levels of hybrid with the breast carcinomas, as compared to lower hybrid levels with RNAs from other epithelial tumors. RNA extracted from breast tissue adjacent to the tumor or from benign breast tumors, demonstrates low or undetectable levels of hybridization. Probing Southern blots with the 60-bp repeat shows that the tumor antigen is highly polymorphic and contains a variable number of tandem repeats (VNTRs). The VNTR nature of the gene was confirmed by probing Southern blots with unique genomic sequences that are physically linked to an isolated gene fragment that also contains the tandem repeat array. Mouse cells transfected with this gene fragment produce tumor antigen that is readily detected by H23 monoclonal antibodies. The allelic forms seen in 10 different primary human tumors demonstrate 100% concordance with the various mRNA species expressed. These studies are extended to the protein forms detected by immunoblot analyses that show both a correlation of the expressed tumor antigen species with the allelic forms as well as significantly increased expression in breast cancer tissue. The above studies unequivocally establish the over-expression of a VNTR gene coding for an epithelial tumor antigen in human breast cancer tissue.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112460     DOI: 10.1111/j.1432-1033.1990.tb15512.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  10 in total

1.  Vaccination against tumor cells expressing breast cancer epithelial tumor antigen.

Authors:  M Hareuveni; C Gautier; M P Kieny; D Wreschner; P Chambon; R Lathe
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines.

Authors:  P A Poland; C L Kinlough; M D Rokaw; J Magarian-Blander; O J Finn; R P Hughey
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

3.  MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.

Authors:  Sean P Pitroda; Nikolai N Khodarev; Michael A Beckett; Donald W Kufe; Ralph R Weichselbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

4.  Circulating tumor-associated antigens detected by monoclonal antibodies against the polypeptide core of mucin--comparison of antigen MUSE11 with CA15-3.

Authors:  Y Hinoda; H Kakiuchi; N Nakagawa; Y Ohe; T Sugiyama; M Tsujisaki; K Imai; A Yachi
Journal:  Gastroenterol Jpn       Date:  1992-06

5.  Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene.

Authors:  M Abe; D Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

6.  Differential expression of MUC genes in endometrial and cervical tissues and tumors.

Authors:  Vidya Hebbar; Gautam Damera; Goverdhan P Sachdev
Journal:  BMC Cancer       Date:  2005-09-27       Impact factor: 4.430

7.  Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy.

Authors:  Riva Kovjazin; Galit Horn; Nechama I Smorodinsky; Michael Y Shapira; Lior Carmon
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  MUC1-ARF-A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA.

Authors:  Michael Chalick; Oded Jacobi; Edward Pichinuk; Christian Garbar; Armand Bensussan; Alan Meeker; Ravit Ziv; Tania Zehavi; Nechama I Smorodinsky; John Hilkens; Franz-Georg Hanisch; Daniel B Rubinstein; Daniel H Wreschner
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

Review 9.  Immunotherapy of prostate cancer.

Authors:  S J Freedland; A J Pantuck; J Weider; A Zisman; A S Belldegrun
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 2.862

10.  Genetic regulation of MUC1 alternative splicing in human tissues.

Authors:  W Ng; A X W Loh; A S Teixeira; S P Pereira; D M Swallow
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.